"Synexus to międzynarodowa sieć przychodni, specjalizujących się w prowadzeniu badań klinicznych oraz programów kontrolnych. Pacjenci chorzy przewlekle w ramach akcji kontrolnych mogą skorzystać z bezpłatnych badań i konsultacji."

During the past decade, Synexus Polska Sp. z o.o. Oddzial w Warszawie conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 33 clinical trials were completed, i.e. on average, 89.2% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 22 clinical trials were completed. i.e. 146.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Synexus Polska Sp. z o.o. Oddzial w Warszawie" #1 sponsor was "Pfizer" with 15 trials, followed by "Boehringer Ingelheim" with 4 trials sponsored, "Celgene" with 3 trials sponsored, "Amgen" with 2 trials sponsored and "Coherus Biosciences, Inc." with 2 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Synexus Polska Sp. z o.o. Oddzial w Warszawie" #1 collaborator was "Daiichi Sankyo Co., Ltd." with 1 trials as a collaborator, "Shire" with 1 trials as a collaborator and "Teva Pharmaceutical Industries, Ltd." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Synexus Polska Sp. z o.o. Oddzial w Warszawie" are "Dermatitis, Atopic" (4 trials), "Atopic Dermatitis" (3 trials), "Plaque Psoriasis" (3 trials), "Psoriasis" (3 trials) and "Rheumatoid Arthritis" (3 trials). Many other conditions were trialed in "Synexus Polska Sp. z o.o. Oddzial w Warszawie" in a lesser frequency.

Most popular intervention types in "Synexus Polska Sp. z o.o. Oddzial w Warszawie" are "Drug" (39 trials), "Biological" (6 trials), "Other" (4 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (25 trials), "PF-04965842 100 mg" (3 trials), "PF-04965842 200 mg" (3 trials), "Adalimumab" (2 trials) and "Apremilast 20mg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Synexus Polska Sp. z o.o. Oddzial w Warszawie" are 43 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Synexus Polska Sp. z o.o. Oddzial w Warszawie". undefined are not yet recruiting, 5 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 31 completed trials in Synexus Polska Sp. z o.o. Oddzial w Warszawie, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Synexus Polska Sp. z o.o. Oddzial w Warszawie, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 38 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".